Project R-12247

Effectiveness and cost-effectiveness of a personalised digital prevention network for high-cardiovascular-risk patients. (Research)

Recent studies have shown that cardiovascular prevention throughout Europe is still highly suboptimal. Digital health can play a key role in improving this. In the proposed study, a digitally assisted personalised prevention program will be used to achieve better risk factor control in high-cardiovascular-risk patients, also those without known cardiac disease. Central to the program are patient autonomy and self-care as well as high primary care physician involvement, thus forming a network between patient, primary care physician and specialist care. 150 patients with peripheral artery disease, stroke or transient ischemic attack will be randomised to either usual care or a 6-month smartphone-assisted cardiovascular prevention program, focused on physical activity, healthy nutrition, medication adherence, parameter registration, education, smoking cessation and mental well-being. Outcome analysis will take place at 6 months, 1 year and 2 years. Primary outcome is the composite IPP prevention score. Secondary endpoints include single risk factors, SMART risk score, major adverse cardiac events (MACE), peak VO2, 6MWT walking distance, medication adherence, quality of life (EQ-5D-5L, PHQ-9 and HeartQoL) and cost-effectiveness (using incremental costeffectiveness ratio (ICER)). If successful, this trial may lead to a high-quality, low-cost, patientcentred, personalised prevention approach.

01 November 2021 - 31 October 2023